Holger Eidtmann

Holger Eidtmann

UNVERIFIED PROFILE

Are you Holger Eidtmann?   Register this Author

Register author
Holger Eidtmann

Holger Eidtmann

Publications by authors named "Holger Eidtmann"

Are you Holger Eidtmann?   Register this Author

53Publications

2675Reads

35Profile Views

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.

J Clin Oncol 2016 Apr 23;34(10):1034-42. Epub 2015 Nov 23.

Martine Piccart-Gebhart, Université Libre de Bruxelles, Brussels, Belgium; Eileen Holmes, Eleanor McFadden, and Andrew P. Holmes, Frontier Science (Scotland), Kincraig, Kingussie, United Kingdom; José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; Evandro de Azambuja, Institut Jules Bordet, Brussels, Belgium; Evandro de Azambuja and Stella Dolci, Breast European Adjuvant Study Team, Brussels, Belgium; Amylou C. Dueck and Anne E. McCullough, Mayo Clinic, Scottsdale, AZ; Giuseppe Viale, University of Milan, Milan, Italy; Giuseppe Viale and Aron Goldhirsch, Istituto Europeo di Oncologia, Milan, Italy; Jo Anne Zujewski, National Cancer Institute, Bethesda, MD; Aron Goldhirsch, Ospedale Regionale di Lugano, Viganello-Lugano, Switzerland; Alison Armour, GlaxoSmithKline, Collegeville, PA; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Kathleen I. Pritchard, University of Toronto, Toronto, Ontario, Canada; Liu Tonghua, Peking Union Medical College Hospital, Beijing, People's Republic of China; Liu Tonghua and Binghe Xu, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China; Holger Eidtmann, University Hospital Kiel, Kiel, Germany; Phuong Dinh, Breast International Group, Brussels, Belgium; Serena Di Cosimo, Istituto Nazionale del Tumori, Milan, Italy; Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain; Nadia Harbeck, Frauenklinik der Universität München, Munich, Germany; Sergei Tjulandin, Blokhin Russian Cancer Research Center of RAMS, Moscow, Russia; Young-Hyuck Im, Korean Cancer Study Group, Seoul, South Korea; Young-Hyuck Im, Samsung Medical Center, Seoul, South Korea; Chiun-Shen Huang, National Taiwan University Hospital, Taipei, Republic of China; Véronique Diéras, Institut Curie, Paris, France; David W. Hillman, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Christian Jackisch, Klinikum Offenba

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.62.1797DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872016PMC
April 2016

Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy.

Eur J Cancer 2016 Jan 13;53:65-74. Epub 2015 Dec 13.

Nationales Centrum für Tumorerkrankungen (NCT), Heidelberg, Im Neuenheimer Feld 460, 69120 Heidelberg, Germany; Universitäts-Frauenklinik Heidelberg, Im Neuenheimer Feld 440, 69120 Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2015.09.022DOI Listing
January 2016

PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.

J Clin Oncol 2015 Apr 5;33(12):1334-9. Epub 2015 Jan 5.

Ian J. Majewski, Lorenza Mittempergher, Astrid J. Bosma, and René Bernards, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Paolo Nuciforo, Jose Jimenez, Claudia Aura, Ludmila Prudkin, Maria Carmen Díaz-Delgado, Vall D'Hebron Institute of Oncology; Lorena de la Peña, Spanish Breast Cancer Cooperative Group SOLTI, Barcelona, Spain; Holger Eidtmann, University Hospital Kiel, Kiel; Nadia Harbeck, University of Munich, Munich, Germany; Eileen Holmes, Frontier Science Scotland, Kincraig, United Kingdom; Christos Sotiriou, Debora Fumagalli, and Martine Piccart-Gebhart, Institut Jules Bordet, Université Libre de Bruxelles; Evandro de Azambuja, BrEAST Data Center and Institut Jules Bordet, Brussels, Belgium; Sherene Loi, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; Catherine Ellis, GlaxoSmithKline, Collegeville, PA; and Nikolaus Schultz and José Baselga, Memorial Sloan-Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.55.2158DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5087318PMC
April 2015

PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.

J Clin Oncol 2014 Oct 8;32(29):3212-20. Epub 2014 Sep 8.

Sibylle Loibl, Sana Klinikum, Offenbach; Sibylle Loibl, Gunter von Minckwitz, Sanxing Guo, Stephan Gade, and Valentina Nekljudov, German Breast Group, Neu-Isenburg; Gunter von Minckwitz, Universitäts-Frauenklinik; Fariba Khandan, Agaplesion Markus Krankenhaus; Clemens Heinrichs, OptiPath, Frankfurt; Andreas Schneeweiss and Peter Sinn, Nationales Centrum für Tumorerkrankungen, Heidelberg; Stephan Paepke, Klinikum Rechts der Isar der Technischen Universität, München; Annika Lehmann, Berit Pfitzner, Judith L. Lindner, and Carsten Denkert, Charité Universitätsmedizin; Michael Untch, Helios-Klinikum, Berlin; Mahdi Rezai, Luisenkrankenhaus; Karel Dohnal, Centre for Pathology and Cytology, Düsseldorf; Dirk M. Zahm, SRH Waldklinikum, Gera; Holger Eidtmann, Universitäts-Frauenklinik, Kiel; Jens Huober, Universitäts-Frauenklinik, Ulm; Peter A. Fasching, Universitäts-Frauenklinik, Erlangen; August Dykgers, St Josef Hospital, Dortmund, Germany; Fabrice Andre, Institute Gustave Roussy, Villeueve, France; Christos Sotiriou, Institut Jules Bordet, Brussels, Belgium; and Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.55.7876DOI Listing
October 2014

Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: a sub-study from the NeoALTTO phase III trial.

Breast 2013 Dec 20;22(6):1060-5. Epub 2013 Sep 20.

Breast Cancer Translational Research Laboratory, J.C. Heuson, Université Libre de Bruxelles, Institut Jules Bordet, Brussels, Belgium; Department of Medicine, BrEAST Data Centre, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2013.08.014DOI Listing
December 2013

Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial.

J Clin Oncol 2013 12 18;31(36):4504-11. Epub 2013 Nov 18.

Jose Baselga, Memorial Sloan-Kettering Cancer Center, NY; James G. Greger Jr, GlaxoSmithKline, Collegeville, PA; Hatem A. Azim Jr, Martine Piccart, Evandro de Azambuja, BrEAST Data Centre, Institut Jules Bordet, Université Libre de Bruxelles; Phuong Dinh, Breast International Group, Brussels; Peter Vuylsteke, Sint-Elisabeth Hospital, Namur, Belgium; Dominique Agbor-tarh, Ian Bradbury, Frontier Science, Kincraig, Kingussie, Scotland; Ian Smith, Royal Marsden Hospital, and Institute of Cancer Research, London, United Kingdom; Serena Di Cosimo, IRCCS Fondazione Instituto Nazionale dei Tumori, Milan, Italy; Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain; Christian Jackisch, Kilinikum Offenbach, Offenbach; Bahriye Aktas, Kliniken Essen-Mitte, Evang, Essen; Holger Eidtmann, University Hospital Kiel, Kiel, Germany; Sung-Bae Kim, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; Chiun-Sheng Huang, National Taiwan University Hospital; Ruey Kuen Hsieh, Mackey Memorial Hospital, Taipei, Taiwan; and Lydia Dreosti, University of Pretoria, Pretoria, South Africa.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.50.9448DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5795667PMC
December 2013

Response-guided neoadjuvant chemotherapy for breast cancer.

J Clin Oncol 2013 Oct 3;31(29):3623-30. Epub 2013 Sep 3.

Gunter von Minckwitz, Keyur Mehta, and Sibylle Loibl, Headquarters, German Breast Group, Neu-Isenburg; Jens Uwe Blohmer, St Gertrauden Krankenhaus, Berlin); Serban Dan Costa, Universitäts-Frauenklinik, Magdeburg; Carsten Denkert, Institute for Pathology, Charite, Berlin; Holger Eidtmann, Universitäts-Frauenklink, Kiel; Wolfgang Eiermann and Claus Hanusch, Klinikum zum Roten Kreuz, Munich; Bernd Gerber, Universitäts-Frauenklinik, Rostock; Jörn Hilfrich, Henrietten-Stiftung, Hanover; Jens Huober, Universitäts-Frauenklinik Tübingen, Frauenklinik; Christian Jakisch and Sibylle Loibl, Städtische Kliniken, Offenbach; Gunter von Minckwitz, Universitäts-Frauenklinik, Frankfurt; Sherko Kümmel, Klinikum Essen Mitte, Essen; Stefan Paepke, Universitäts-Frauenklinik rechts der Isar, Munich; Andreas Schneeweiss, National Center for Tumor Diseases, University of Heidelberg; Michael Untch, Helios-Klinikum, Berlin-Buch; Dirk Michael Zahm, Brustzentrum Stiftung Rehabilitation Heidelberg (SRH) Waldkliniken, Gera, Germany; Jens Huober, Kantonsspital, St Gallen, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.45.0940DOI Listing
October 2013

Trastuzumab single-drug therapy after failure of cytotoxic treatment for metastatic breast cancer.

Onkologie 2010 27;33(8-9):425-30. Epub 2010 Jul 27.

Klinikum Mutterhaus der Borromäerinnen gGmbH, Trier, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000318144DOI Listing
January 2011

The anti-tumor effect of bisphosphonates ABCSG-12, ZO-FAST and more ...

Crit Rev Oncol Hematol 2010 Apr;74 Suppl 1:S2-6

Medical University of Vienna; Austrian Breast & Colorectal Cancer Group, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1040-8428(10)70003-2DOI Listing
April 2010

Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study.

J Clin Oncol 2007 Jul 11;25(19):2664-70. Epub 2007 Jun 11.

Department of Obstetrics and Gynaecology, J.W. Goethe-University of Frankfurt, Frankfurt am Main, Frankfurt/Main, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2006.08.8054DOI Listing
July 2007

Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trial.

Ann Surg Oncol 2006 Nov 17;13(11):1434-42. Epub 2006 Sep 17.

Department of Obstetrics and Gynecology, J. W. Goethe University, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-006-9011-2DOI Listing
November 2006

Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer.

J Natl Cancer Inst 2004 Aug;96(15):1141-51

Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, and Jonsson Comprehensive Cancer Center, Los Angeles, CA 90095-7077, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djh198DOI Listing
August 2004